according to the Globally Harmonized System



Furosemide Solid Formulation

Version 4.1	Revision Date: 30.09.2023		S Number: 3060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
1. PRODU	JCT AND COMPANY ID	ENT	IFICATION	
Prod	uct name	:	Furosemide Soli	d Formulation
Man	ufacturer or supplier's o	deta	ils	
Com	pany	:	MSD	
Addr	ess	:	Briahnager - Off Wagholi - Pune -	Pune Nagar Road - India 412 207
Telep	phone	:	+1-908-740-400	0
Eme	rgency telephone numbe	er :	+1-908-423-6000	0

: EHSDATASTEWARD@msd.com

Recommen	de	d use o	f the	chemical	and	restrictions of	on use
_		-					

Recommended use	:	Veterinary product
Restrictions on use	:	Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

E-mail address

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Specific target organ toxicity -	:	Category 1 (Kidney, Liver)
repeated exposure		

2

GHS label elements

Hazard pictograms :



Signal word

Hazard statements

: H372 Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary statements

Prevention:

P260 Do not breathe dust.P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:
4.1	30.09.2023

SDS Number: 658060-00015

Date of last issue: 04.04.2023 Date of first issue: 03.05.2016

Response:

P319 Get medical help if you feel unwell.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

Mixture

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture :

Components

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	>= 50 - < 70
Furosemide	54-31-9	>= 10 - < 20
Cellulose	9004-34-6	>= 1 - < 5

4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.
In case of eye contact	:	
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and	:	Causes damage to organs through prolonged or repeated exposure.
delayed		Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	:	Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

according to the Globally Harmonized System



Furosemide Solid Formulation

Version 4.1	Revision Date: 30.09.2023		S Number: 3060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
media	fic hazards during fire-	:	concentrations, ar potential dust exp	CO2) dust; fine dust dispersed in air in sufficient ad in the presence of an ignition source is a
Hazar ucts	dous combustion prod-	:	Nitrogen oxides (N Carbon oxides Sulphur oxides Chlorine compour	
ods	fic extinguishing meth-	:	cumstances and t Use water spray to Remove undamag so. Evacuate area.	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	al protective equipment	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfac- es, as these may form an explosive mixture if they are re- leased into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Static electricity may accumulate and ignite suspended dust causing an explosion.

according to the Globally Harmonized System



Furosemide Solid Formulation

Version 4.1	Revision Date: 30.09.2023	SDS Number: 658060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
	al/Total ventilation ice on safe handling	and bonding, Use only with Do not breat Do not swalle Avoid contac Avoid prolon Wash skin th Handle in ac practice, bas sessment Minimize dus Keep contair Keep away fi Take precau Do not eat, d	by. t with eyes. ged or repeated contact with skin. oroughly after handling. cordance with good industrial hygiene and safety ed on the results of the workplace exposure as- st generation and accumulation. her closed when not in use. rom heat and sources of ignition. tionary measures against static discharges. Irink or smoke when using this product. prevent spills, waste and minimize release to the
Con	ditions for safe storage		erly labelled containers. Indance with the particular national regulations.
Mate	erials to avoid		with the following product types:

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Cellulose

Components with workplace control parameters							
Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis			
Starch	9005-25-8	TWA	10 mg/m3	ACGIH			
Furosemide	54-31-9	TWA	200 µg/m3	Internal			
		TWA	OEB 2 (>=100 - 1000 ug/m3)	Internal			

9004-34-6

with workplace (~ . . 1

Engineering measures	 Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Personal protective equipment	nt
Hand protection	 If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Particulates type
Material	Chemical-resistant gloves
Eye protection	 Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

TWA

10 mg/m3

ACGIH



according to the Globally Harmonized System

Furosemide Solid Formulation

Version	Revision Date: 30.09.2023	SDS Number:	Date of last issue: 04.04.2023
4.1		658060-00015	Date of first issue: 03.05.2016
	and body protection ne measures	 potential for dir aerosols. Work uniform of Il exposure to of flushing system place. When using do Wash contamir The effective of engineering con appropriate deg 	chemical is likely during typical use, provide eye as and safety showers close to the working not eat, drink or smoke. hated clothing before re-use. beration of a facility should include review of ntrols, proper personal protective equipment, gowning and decontamination procedures, ne monitoring, medical surveillance and the

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	yellow
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available

according to the Globally Harmonized System



Furosemide Solid Formulation

Versic 4.1	on	Revision Date: 30.09.2023		S Number: 3060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
S	Solubilit Wate	y(ies) er solubility	:	No data available	9
	Partitior	n coefficient: n-	:	No data available	9
		nition temperature	:	No data available	9
D	Decomp	oosition temperature	:	No data available	9
V	/iscosit/ Visco	y osity, kinematic	:	No data available	9
E	Explosiv	ve properties	:	Not explosive	
С	Dxidizin	g properties	:	The substance o	r mixture is not classified as oxidizing.
Ν	Nolecul	ar weight	:	Not applicable	
P	Particle	size	:	No data available	9

10. STABILITY AND REACTIVITY

:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
:	Heat, flames and sparks. Avoid dust formation.
:	Oxidizing agents
	:

11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg
		Method: Calculation method

Components:

Starch:

according to the Globally Harmonized System



Furosemide Solid Formulation

Vers 4.1	ion	Revision Date: 30.09.2023		9S Number: 8060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
	Acute o	ral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg
	Acute d	ermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg
	Furose	mide:			
	Acute o	ral toxicity	:	LD50 (Rat): 2,600	mg/kg
				LD50 (Dog): 2,000) mg/kg
				LD50 (Rabbit): 80	0 mg/kg
	Acute to adminis	oxicity (other routes of tration)	:	LD0 (Humans): 6 Application Route	
				LD50 (Rat): 800 m Application Route	
	Cellulo	se:			
	Acute o	ral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg
	Acute ir	nhalation toxicity	:	LC50 (Rat): > 5.8 Exposure time: 4 Test atmosphere:	h
	Acute d	ermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg
	Skin co	prrosion/irritation			
	Not clas	ssified based on availa	ble	information.	
	0		4 - 41		

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species	:	Rabbit
Result	:	No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Starch:

: Maximisation Test
: Skin contact
: Guinea pig
: negative

according to the Globally Harmonized System



Furosemide Solid Formulation

Version 4.1	Revision Date: 30.09.2023		S Number: 3060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
	cell mutagenicity assified based on av	ailable	information.	
<u>Comp</u>	oonents:			
Starc	h:			
Genot	toxicity in vitro	:	Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
Furos	semide:			
Genot	toxicity in vitro	:	Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
				vitro mammalian cell gene mutation test nouse lymphoma cells e
			thesis in mam	IA damage and repair, unscheduled DNA syn- malian cells (in vitro) nammalian liver cells ve
				romosome aberration test in vitro Chinese hamster ovary cells e
			malian cells	vitro sister chromatid exchange assay in mam- Chinese hamster cells ve
Genot	toxicity in vivo	:	Test Type: Ma cytogenetic as Species: Mous Application Ro Result: negation	se pute: Ingestion
				oute: Ingestion
Cellul	lose:			
	toxicity in vitro	:	Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
			Test Type: In Result: negati	vitro mammalian cell gene mutation test ve
Genot	toxicity in vivo	:	Test Type: Ma	mmalian erythrocyte micronucleus test (in vivo

according to the Globally Harmonized System



Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	658060-00015	Date of first issue: 03.05.2016

cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Furosemide:

Species Application Route Exposure time LOAEL Result	: : : :	Rat Ingestion 104 weeks 16 mg/kg body weight equivocal
Species Application Route Exposure time LOAEL Result		Mouse Ingestion 2 Years 91 mg/kg body weight positive

Cellulose:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

Reproductive toxicity

Not classified based on available information.

Components:

Furosemide:

Effects on fertility	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion General Toxicity - Parent: NOAEL: 90 mg/kg body weight Result: No effects on reproduction parameters
	Test Type: One-generation reproduction toxicity study Species: Mouse Application Route: Ingestion General Toxicity - Parent: NOAEL: 200 mg/kg body weight Result: No effects on reproduction parameters
Effects on foetal develop- ment	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion General Toxicity Maternal: LOAEL: 50 mg/kg body weight Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: No embryotoxic effects, No teratogenic effects

according to the Globally Harmonized System



Furosemide Solid Formulation

Versio 4.1		Revision Date: 0.09.2023		S Number: 8060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
				Species: Mouse Application Route General Toxicity M	y/early embryonic development : Ingestion /laternal: LOAEL: 25 mg/kg body weight oxicity observed., Fetal effects
				Species: Rabbit Application Route General Toxicity M Developmental To	y/early embryonic development : Ingestion Maternal: LOAEL: <= 12 mg/kg body weight oxicity: LOAEL: 12.5 mg/kg body weight oxicity observed., Reduced number of viable
				Species: Rabbit Application Route General Toxicity M	y/early embryonic development : Ingestion /laternal: LOAEL: 15 mg/kg body weight oxicity observed., No effects on foetal de-
с	ellulose	;			
E	ffects or	n fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
	ffects or nent	n foetal develop-	:	Test Type: Fertility Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion
		ingle exposure ified based on availa	ble	information.	
		epeated exposure	م ما م	······································	
	ompon		une	y, Liver) through p	rolonged or repeated exposure.
	urosem				
E T	xposure arget Or ssessm	routes gans	:	Ingestion Kidney Shown to produce centrations of 10 r	e significant health effects in animals at con- mg/kg bw or less.
R	epeated	d dose toxicity			
<u>c</u>	ompon	ents:			
S	starch:				
S	pecies		:	Rat	

according to the Globally Harmonized System



Furosemide Solid Formulation

Version 4.1	Revision Date: 30.09.2023	SDS Number: 658060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
Apr Exp	AEL blication Route bosure time thod	: >= 2,000 mg/ : Skin contact : 28 Days : OECD Test 0	
Spe NO LO/ App Exp Tar Syr	osemide: ecies AEL AEL olication Route oosure time get Organs nptoms marks	: Dog : 4 mg/kg : 8 mg/kg : Ingestion : 12 Months : Kidney : Blood disorde : Significant to	ers xicity observed in testing
Spe NO App Exp Asj	Iulose: acies AEL blication Route oosure time biration toxicity classified based on ava	: Rat : >= 9,000 mg/ : Ingestion : 90 Days ilable information.	/kg
Exp	perience with human ex	kposure	
Fur Inha Skii Eye	mponents: osemide: alation n contact e contact estion	: Remarks: Ma : Remarks: Ma : Symptoms: k ance, dry mo	ay be harmful if inhaled. ay irritate skin. ay cause eye irritation. Kidney disorders, Headache, electrolyte imbal- uth, hearing loss, Irregular cardiac activity, Gas- disturbance, hypotension
12. ECC		ON	
	otoxicity nponents:		
	osemide: icity to fish	: LC50: 500 m Exposure tim	
	lulose: icity to fish	Exposure tim	as latipes (Japanese medaka)): > 100 mg/l e: 48 h sed on data from similar materials

according to the Globally Harmonized System



Furosemide Solid Formulation

Vers 4.1	sion	Revision Date: 30.09.2023		DS Number: 8060-00015	Date of last issue: 04.04.2023 Date of first issue: 03.05.2016
	Persis	stence and degradabi	lity		
	<u>Comp</u>	onents:			
	Cellul Biodeg	ose: gradability	:	Result: Readily b	iodegradable.
	Bioace	cumulative potential			
	<u>Comp</u>	onents:			
	Partitic	emide: on coefficient: n- ol/water	:	log Pow: 2.03	
	No dat	ty in soil a available adverse effects			
	No dat	a available			
13.	DISPOS	SAL CONSIDERATIO	NS		
	•	sal methods		De net dianese et	
		from residues minated packaging	:	Dispose of in acc	waste into sewer. ordance with local regulations. should be taken to an approved waste han-
	Jonal	initiated packaging	•		

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14	TR/	NSP	ORT	INFOR	MATION
14.	111/	111051			

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user Not applicable



according to the Globally Harmonized System

Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	658060-00015	Date of first issue: 03.05.2016

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture


The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Revision Date	:	30.09.2023
Further information		
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
Date format	:	dd.mm.yyyy
Full text of other abbreviat	ions	
ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA	:	8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evalua-





Furosemide Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	658060-00015	Date of first issue: 03.05.2016

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN